Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
April 04, 2023 08:00 ET
|
Phathom Pharmaceuticals
Favorable feedback following meeting with the U.S. Food and Drug Administration (FDA) allows for planned resubmission of erosive esophagitis new drug application (NDA) this quarterCombined commercial...
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 08, 2022 17:00 ET
|
Phathom Pharmaceuticals
Patient enrollment completed for Phase 3 non-erosive gastroesophageal reflux disease (NERD) daily dosing trial with topline data for primary endpoint expected in Q1 2023 Obtained commitment for up to...
Biomerica Reports Fiscal 2022 Year End Results
August 29, 2022 16:41 ET
|
Biomerica, Inc.
Revenues increase 162% for fiscal 2022 vs fiscal 2021 Revenues for fiscal Q4 2022 up 403% vs. fiscal Q4 2021 IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the...
Helicobacter Pylori Non-invasive Testing Market Revenue to Cross $800.04Mn, Globally, by 2028 to Growing at 4.4% CAGR – Study by The Insight Partners
August 24, 2022 06:00 ET
|
The Insight Partners
New York, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market Forecast to 2028 – COVID-19 Impact...
Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
June 01, 2022 08:15 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022
May 24, 2022 12:15 ET
|
Phathom Pharmaceuticals
Results from an investigational Phase 3 PHALCON-EE trial demonstrating superior healing at week 2 in patients with LA Grade C/D (moderate-to-severe) erosive esophagitis and superior maintenance of...
Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting
May 17, 2022 08:01 ET
|
Phathom Pharmaceuticals
New investigational data evaluating vonoprazan in erosive esophagitis (EE) Research highlights real-world evidence of unmet needs that exists for the treatment of Helicobacter pylori (H. pylori)...
Biomerica Announces CE Mark for Its H. pylori Diagnostic Test, hp+detect™
May 12, 2022 08:19 ET
|
Biomerica, Inc.
- Attaining CE Mark is a major step toward commercialization – - World Health Organization (WHO) lists H. pylori among the 16 antibiotic-resistant bacteria that pose the greatest threat to human...
Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates
May 10, 2022 08:00 ET
|
Phathom Pharmaceuticals
U.S. Food and Drug Administration (FDA) approval received for VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for treatment of H....
Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital
May 04, 2022 08:01 ET
|
Phathom Pharmaceuticals
Upfront payment of $100 million, an additional $160 million available upon FDA approval of vonoprazan for treatment of erosive esophagitis (EE)Provides capital for launch of vonoprazan in H. pylori...